Truist Bullish on ArriVent: $45 Target on Firmonertinib’s Lung Cancer Potential
Truist is bullish on ArriVent, rating Buy and seeing firmonertinib as a strong lung cancer drug with up to $1.1B peak sales.
/ 124 items
#XY Analyst Up/Down↓
Sensei Biotherapeutics Gets Wall Street Backing as PIKTOR Advances in Breast & Endometrial Cancer
Cantor is bullish on Sensei Biotherapeutics for its cancer drug PIKTOR, with Phase 2 data soon as a key stock catalyst.
TD Cowen & Evercore ISI Praise “Compelling” EDIT-401 Data as Editas Eyes 2026 Human Trials
Editas’ gene therapy EDIT-401 cut bad cholesterol ~90% in animals; analysts bullish; human trials expected in 2026.
Jefferies Sees Hemlibra-Like Potential in Hemab Therapeutics, Starts Coverage with Buy Rating
Hemab targets rare bleeding diseases with new treatments, strong cash, and big growth potential, with analysts seeing ~50% upside.
Tectonic Therapeutics Gets Strong Buy Upgrade: Two Potential Blockbusters in Focus
Raymond James upgraded Tectonic Therapeutics to Strong Buy and raised its price target to $81. Analyst highlights the potential of TX45 and TX2100 as two blockbuster candidates at a low valuation.
Mizuho Turns Positive on Q32 Bio’s Bempikibart, Initiates Coverage with Outperform Rating
Mizuho sees Q32 Bio upside with $14 target vs ~$5.50, boosted by bempikibart alopecia drug progress and 2026 data.